Alejo Rodríguez‐Vida
A5091309316- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Urinary and Genital Oncology Studies
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Prostate Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- PI3K/AKT/mTOR signaling in cancer
- Renal and related cancers
- Epigenetics and DNA Methylation
- Esophageal Cancer Research and Treatment
- Estrogen and related hormone effects
- Economic and Financial Impacts of Cancer
- Peptidase Inhibition and Analysis
- Hormonal and reproductive studies
- CAR-T cell therapy research
- Bone health and treatments
- Frailty in Older Adults
- Fibroblast Growth Factor Research
- Cancer Cells and Metastasis
- Multiple and Secondary Primary Cancers
Hospital Del Mar
2016-2025
Centro de Investigación Biomédica en Red de Cáncer
2019-2025
Municipal Institute for Medical Research
2016-2025
Hospital del Mar Research Institute
2016-2025
Institut de recherche mathématique de Rennes
2023
Parc de Salut
2018-2021
Guy's and St Thomas' NHS Foundation Trust
2013-2015
Guy's Hospital
2013-2014
Institut d'Investigació Biomédica de Bellvitge
2014
St. Thomas Hospital
2013
Germline mutations in DNA damage repair (DDR) genes are identified a significant proportion of patients with metastatic prostate cancer, but the clinical implications these remain unclear. This prospective multicenter cohort study evaluated prevalence and effect germline DDR (gDDR) on castration-resistance cancer (mCRPC) outcomes.Unselected were enrolled at diagnosis mCRPC screened for gDDR 107 genes. The primary aim was to assess impact ATM/BRCA1/BRCA2/ PALB2 cause-specific survival (CSS)...
Metastatic papillary renal cancer (PRC) has poor outcomes, and new treatments are required. There is a strong rationale for investigating mesenchymal epithelial transition receptor (MET) programmed cell death ligand-1 (PD-L1) inhibition in this disease. In study, the combination of savolitinib (MET inhibitor) durvalumab (PD-L1 investigated.This single-arm phase II trial explored (1,500 mg once every four weeks) (600 daily; ClinicalTrials.gov identifier: NCT02819596). Treatment-naïve or...
4506 Background: Atezolizumab is a PD-L1 inhibitor which licenced in metastatic urothelial cancer. This study investigates the efficacy and safety of neoadjuvant atezolizumab given prior to cystectomy operable muscle invasive transitional cell carcinoma bladder Methods: single arm phase 2 investigated cycles (1200mg Q3) cancer (T2-4N0M0). Pathological complete response (pCR) occurring ≥20% patients was primary endpoint. Biomarker analysis on sequential tissue co-primary Cross sectional...
Background Immune checkpoint inhibitors (ICIs) represent an appealing treatment for patients with advanced urothelial cancer (aUC) and a poor performance status (PS). However, the benefit of ICIs PS remains unknown. It was hypothesized that Eastern Cooperative Oncology Group (ECOG) (≥2 vs 0‐1) would correlate shorter overall survival (OS) in receiving ICIs. Methods In this retrospective cohort study, clinicopathologic, treatment, outcome data were collected aUC who treated at 18 institutions...
This first-in-human study evaluated RO7122290, a bispecific fusion protein carrying split trimeric 4-1BB (CD137) ligand and fibroblast activation α (FAP) binding site that costimulates T cells for improved tumor cell killing in FAP-expressing tumors. Patients with advanced or metastatic solid tumors received escalating weekly intravenous doses of RO7122290 as single agent ( n = 65) combination 1200-milligram fixed dose the anti–programmed death-ligand 1 (anti–PD-L1) antibody atezolizumab...
Abstract High-grade T1 (HGT1) bladder cancer is the highest risk subtype of non–muscle-invasive with unpredictable outcome and poorly understood factors. Here, we examined association somatic mutation profiles nonrecurrent disease (GO, good outcome), recurrence (R), or progression (PD) in a cohort HGT1 patients. Exome sequencing was performed on 62 15 matched normal tissue samples. Both tumor only (TO) paired analyses were performed, focusing 95 genes known to be mutated cancer. Somatic...
5007 Background: Skeletal fractures, pathological or not, are a frequent and underestimated side-effect of systemic treatment metastatic castration resistant prostate cancer (mCRPC). The ERA223 trial (NCT02043678) was recently unblinded following the report significant increase in fracture rates when abiraterone is combined with Ra223. Hence, FDA EMA advised against this combination. question whether mandated use bone protecting agents (BPA), zoledronic acid denosumab, would have mitigated...
Abstract Background ATLAS evaluated the efficacy and safety of PARP inhibitor rucaparib in patients with previously treated locally advanced/unresectable or metastatic urothelial carcinoma (UC). Methods Patients UC were enrolled independent tumor homologous recombination deficiency (HRD) status received 600 mg BID. The primary endpoint was investigator-assessed objective response rate (RECIST v1.1) intent-to-treat HRD-positive (loss genome-wide heterozygosity ≥10%) populations. Key secondary...
545 Background: Metastatic papillary renal cancer (PRC) has poor outcomes and there is need for new treatments. There a strong rationale investigating MET PD-L1 inhibition in this disease. In study, we investigate savolitinib (MET inhibitor) durvalumab (PD-L1 together. Methods: This single arm phase I/II trial explored at starting doses of 1500mg Q4W 600mg OD respectively, with 4wk run-in. Treatment naïve or previously treated patients metastatic PRC were included. Response rate (RR) (RECIST...
Urinary tract cancer can be pure urothelial carcinoma, nonurothelial carcinoma or variant (defined here as mixed carcinoma). Little is known regarding outcomes for patients with receiving immune checkpoint inhibitors. We hypothesized that does not compromise inhibitor efficacy in advanced carcinoma.We performed a retrospective cohort study across 18 institutions. Demographic, clinicopathological, treatment and data were collected who received Patients divided into vs subgroups, further by...